Opportunities to Improve the Quality of Care for Patients with COPD in
Long-term Care Settings e-Monograph
Release Date: December 5, 2016
Expiration Date: December 5, 2017
Expected time to completion: 0.5 hour(s)
Meenakshi Patel, MD
Associate Professor of Medicine
Department of Medicine
Division of Geriatrics
Boonshoft School of Medicine
Wright State University
Valley Medical Primary Care
An estimated 15.7 million adults have been told by a physician or other health professional that they have chronic obstructive pulmonary disease (COPD). Adults with COPD have increased comorbid conditions, difficulty walking or climbing stairs, or need special equipment to manage health problems compared with adults without COPD. Moreover, COPD is the 3rd most common cause of death in the US, just behind cancer and heart disease. However, COPD is listed as one of the conditions in which hospitalizations are preventable to some degree. Many of the patients at risk for hospitalization are elderly and come from long-term care settings.
In fact, the prevalence of COPD in long-term care facilities was reported in one study as 12.4%. Compared with long-term care residents without COPD, emergency department visits or overnight hospital stays were more prevalent among residents with COPD. Furthermore, arthritis, depression, congestive heart failure, diabetes, coronary heart disease, and asthma are more common among residents with COPD than those without COPD. These data highlight an important population of patients in which improvements in care are necessary to change current patient outcomes.
This program will review important considerations for patients with COPD in the long-term care setting.
This educational initiative has been designed for internal medicine and primary care physicians who provide long-term care for patients with COPD.
Upon completion of this educational activity, participants should be able to:
- Recognize the need for long-acting bronchodilators as maintenance treatment for patients with COPD in long-term care settings
- Identify physical and cognitive limitations that may affect successful medication delivery in patients with COPD
- Evaluate patient needs and provide a long-acting bronchodilator maintenance therapy delivery option matched to these needs
Directions to Learner
There are no fees for participating and receiving CME credit for this activity. During the period December 5, 2016 through December 5, 2017, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be sent to you within 4 weeks.
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Integrity Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest (COI)
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Meenakshi Patel, MD
Consultant: Acadia, Sanofi, Sunovion Pharmaceuticals, Inc.
Research support: AstraZeneca, Avanir, Avid, GlaxoSmithKline, Janssen, Lundbeck, Navidea, Pfizer, Sanofi, Suven, Takeda
Speaker: Actavis, Avanir, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, Sunovion Pharmaceuticals, Inc.
Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sunovion Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc. and Sunovion Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity CE, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and...(continued)
Minimum System Requirements
Windows XP, Windows 2000, Windows Vista, and Windows 7
Intel Pentium 4, 2.33 + GHz (or equivalent)
Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer is not recommended.
Mac OS X v10.4 or later
1.8GHz or faster (or equivalent)
Intel Core Duo 1.33GHz or faster (or equivalent)
Adobe® Flash® Player 10
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
|Provided by Integrity Continuing Education, Inc.|
|Supported by an educational grant from Sunovion Pharmaceuticals, Inc.|